Oyster Point Pharma Inc

Oyster Point Pharma — Technical Presentation (July 2021)

8 slides from Oyster Point Pharma's technical presentation, Jul 1, 2021

  1. Slide 1: Varenicline Activity on SARS-CoV-2 Infection

    Varenicline Activity on SARS-CoV-2 Infection July 1, 2021 Exhibit 99.1

  2. Slide 2: Disclaimers and Forward-looking Statements

    Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of the “Company regarding the future of the Company’s business,

  3. Slide 3: Varenicline Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Calu-3 Cells

    Varenicline was Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Calu-3 Cells

  4. Slide 4: SARS-CoV-2 (wildtype) Infectivity in Caco-2

    Varenicline was Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Caco-2 Cells

  5. Slide 5: SARS-CoV-2-alpha (UK Variant)

    Varenicline was Observed to Reduce SARS-CoV-2-alpha (UK Variant) Infectivity in Calu-3 Cells

  6. Slide 6: SARS-CoV-2-beta (South African Variant)

    Varenicline was Observed to Reduce SARS-CoV-2-beta (South African Variant) Infectivity in Calu-3 Cells

  7. Slide 7: Study Design for SARS-CoV-2 Challenge in Rhesus Macaques

    Study Design for SARS-CoV-2 Challenge in Rhesus Macaques

  8. Slide 8: Effect of OC-01 (varenicline) Nasal Spray on SARS-CoV-2 gRNA and sgRNA in Rhesus Macaques

    Effect of OC-01 (varenicline) Nasal Spray on SARS-CoV-2 gRNA and sgRNA in Rhesus Macaques SARS-CoV-2 gRNA and sgRNA were measured by qRT-PCR in nasal swab samples taken at Day 2, Day 3, Day 5, and Day 6 of the study (equivalent to post-challenge days 1, 2, 4, and 5) for the control animals and Day 2

Oyster Point Pharma — Technical Presentation (July 2021) on 6ix